MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients

The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy

(2020) T. Szarvas et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis

(2020) Ann Taber et al.   Nature Communications

Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients

(2020) Csilla Olah et al.   Diagnostics

Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer

(2019) Ulrich Krafft et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

A húgyhólyag urothelialis daganatainak molekuláris alcsoportbeosztása és annak klinikai vonatkozásai

(2019) Tibor Szarvas et al.   ORVOSI HETILAP

Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer

(2018) Tibor Szarvas et al.   BJU INTERNATIONAL

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines

(2018) Margaretha Skowron et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

(2017) Roland Seiler et al.   EUROPEAN UROLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

(2017) Yang‐Min Ning et al.   ONCOLOGIST

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients

(2014) Yong Huang et al.   MEDICAL ONCOLOGY

Inferring tumour purity and stromal and immune cell admixture from expression data

(2013) Kosuke Yoshihara et al.   Nature Communications

A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer

(2012) Joshua J. Meeks et al.   EUROPEAN UROLOGY

Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer

(2011) Iver Nordentoft et al.   BMC CANCER

Matrix metalloproteinases and their clinical relevance in urinary bladder cancer

(2011) Tibor Szarvas et al.   Nature Reviews Urology

Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer

(2010) Tibor Szarvas et al.   CANCER SCIENCE

Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines

(2009) Anna Ansell et al.   ORAL ONCOLOGY

The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin

(2009) Vanessa Almendro et al.   PLoS One

Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer

(2008) Hui Liu et al.   CANCER SCIENCE

Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells

(2008) Hui Liu et al.   MOLECULAR BIOLOGY REPORTS